• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Schering resumes contrast sales in Brazil

Article

Schering resumes contrast sales in BrazilGerman pharmaceutical developer Schering has resumed selling its contrast media products in Brazil. The reinstatement comes after Brazilian authorities forced a halt to sales of all Schering products in the

Schering resumes contrast sales in Brazil

German pharmaceutical developer Schering has resumed selling its contrast media products in Brazil. The reinstatement comes after Brazilian authorities forced a halt to sales of all Schering products in the country after revelations that placebo birth control pills manufactured by the company were sold on the Brazilian market.

The controversy erupted in late June, after the Brazilian media reported that a placebo batch of Microvlar, a Schering birth control pill, had been released on the market and sold to Brazilian women. At least seven women have come forward claiming to have become pregnant after taking the placebo pills.

According to Schering, the company manufactured the placebo pills as part of a test run of a new packaging machine. The batch, consisting of 600,000 Microvlar packages, was supposed to be destroyed after the test run, but Schering believes that some packages were stolen and illegally sold. Schering has recalled all Microvlar pills on the Brazilian market and has collected 900,000 packages.

The controversy prompted a face-off between Schering and Brazilian authorities, who ordered Schering in early July to stop sales of all its products, including contrast media. That ban was lifted in mid-July on contrast media and other Schering pharmaceuticals, with the exception of Microvlar, which remains under suspension. The sales ban had a minimal effect on Schering's contrast media sales, which only constitute 9% of the company's revenues in Brazil, according to a company spokesperson.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.